Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project.
Embryonic allografted human tissue in patients with Parkinson's disease has been shown to survive and ameliorate many of the symptoms of this disease. Despite this success, the practical problems of using this tissue coupled to the ethical restrictions of using aborted human fetal tissue have lead to an exploration for alternative sources of suitable material for grafting, including xenogeneic embryonic dopaminergic-rich neural tissue. Nevertheless, xenografted neural tissue itself generates a number of practical, ethical, safety, and immunological issues that have to be addressed prior to any clinical xenotransplant program. In this article we review these critical issues and set out the criteria that we consider need to be met in the development of our clinical xenotransplantation research programs. We advocate that these, or similar, criteria should be adopted and made explicit by other centers contemplating similar clinical trials.
Barker
R A
RA
Department of Experimental Psychology and Centre for Brain Repair, University of Cambridge, UK. rab46@cus.cam.ac.uk
Kendall
A L
AL
Widner
H
H
D000818:Animals; D016380:Brain Tissue Transplantation; D017690:Cell Transplantation; D002986:Clinical Trials as Topic; D020077:Endogenous Retroviruses / Q000302:isolation & purification; D016332:Fetal Tissue Transplantation; D005865:Gestational Age; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D010300:Parkinson Disease / Q000601:surgery*; D018570:Risk Assessment; D012449:Safety; D013047:Specific Pathogen-Free Organisms; D013552:Swine; D014183:Transplantation, Heterologous